HEAL:SW:SW-iShares Healthcare Innovation UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 7.83

Change

-0.12 (-1.55)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.03 (+0.25%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.02 (+0.07%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.37 (+1.38%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-573.00 (-6.86%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-103.00 (-1.98%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-20.60 (-1.27%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-16.00 (-0.73%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.53 (+0.71%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.68 (+0.62%)

USD 130,595.12B

ETFs Containing HEAL:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.62% 33% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.62% 33% F 39% F
Trailing 12 Months  
Capital Gain 20.07% 69% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.07% 69% C- 71% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.26% 34% F 37% F
Dividend Return 2.26% 34% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.54% 62% D 66% D+
Risk Adjusted Return 34.61% 28% F 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.